Brittany Emmerson
机构：Peter MacCallum Cancer Centre, Peter MacCallum Cancer Foundation
发表论文 15 篇 · 总被引 229 次 · h-index 8
代表论文
- First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study (2025 · The Lancet Oncology · 被引 60)
- AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol) (2022 · Frontiers in Medicine · 被引 44)
- Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T (2024 · Journal of Nuclear Medicine · 被引 32)
- Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial (2025 · The Lancet Oncology · 被引 19)
- Quantitative calibration of Tb-161 SPECT/CT in view of personalised dosimetry assessment studies (2024 · EJNMMI Physics · 被引 18)
- VIOLET: A phase I/II trial evaluation of radioligand treatment in men with metastatic castration-resistant prostate cancer with [161Tb]Tb-PSMA-I&T. (2023 · Journal of Clinical Oncology · 被引 18)